AvenCell’s $112M Boost to Propel Its CAR-T Therapy for Acute Myeloid Leukemia
In the intricate world of cancer treatment, AvenCell Therapeutics has made waves with its recent achievement. The company successfully raised $112 million in a Series B funding round to further develop its promising CAR-T cell therapies targeting acute myeloid leukemia (AML). This funding is a significant stride toward tackling what many in the industry call “the […]
AvenCell’s $112M Boost to Propel Its CAR-T Therapy for Acute Myeloid Leukemia Read More »